Mark Esser, PhD, was appointed the inaugural chief scientific officer and head of the upcoming Paul and Diane Manning Institute of Biotechnology at Charlottesville-based University of Virginia. In his ...

Chemomab Therapeutics, Ltd ., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that David ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...

As the lines between beauty, health and tech blur, future product innovation will be driven by regenerative science and ...

Mark Esser, an executive at Big Pharma firm AstraZeneca, has been named the inaugural leader of UVa's future Manning ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

HATFIELD, PA — Biolyst Scientific has appointed Jay Hexamer as its new Chief Executive Officer, effective immediately, to ...

Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for ...

Prior to joining Korro, Dr. Vincent served as Chief Scientific Officer at Affini-T Therapeutics leading efforts ... Prior to joining Korro, Mr. Dolan held key finance roles with Unity Biotechnology, ...

Dr. Vincent, who previously served as Chief Scientific Officer at Affini-T Therapeutics and held leadership roles at Takeda and Sanofi, remarked on the potential of Korro’s RNA-editing technology to ...